CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such ...

Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that ...

AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, issues at a Novo plant are ...

A deal valuing the Boston biotech’s stock at $700 million hands BioCryst a long-acting injectable for hereditary angioedema ...

However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...

A settlement could extend the exclusivity of the world’s best-selling HIV medicine to 2036. Elsewhere, an AstraZeneca drug ...

Bringing in a recruitment partner early gives sponsors the chance to test their protocols with real patients and gather ...

Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that ...

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company ...

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a ...

HHS employees across multiple divisions have received reduction-in-force notices,” an administration spokesperson confirmed.

Nilo Therapeutics, which launched Wednesday, is trying to develop drugs that regulate inflammation and the immune system by ...